Aprepitant to Improve Same Day Discharge for TKA

ConditionPONV
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-90
SponsorEndeavor Health

About this trial

The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.

Eligibility criteria

Qualifiers

Receiving primary, unilateral elective TKA with or without abductor canal block

Asa I-III

Age 18-90

Ability to receive ondansetron and dexamethasone

Disqualifiers

Allergy to any of the anti-emetics being administered

Current treatment of pimozide

Emergent surgery

Revision/ multiple revisions of TKA

Trial design

Treatments tested in this trial

  • Aprepitant Injection
  • Ondansetron (Zofran)
  • Dexamethasone
  • Placebo

Treatment groups

350 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Endeavor Health

Lead sponsor

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.)

Collaborator